Clinical Trials Logo

Lymphoma clinical trials

View clinical trials related to Lymphoma.

Filter by:

NCT ID: NCT06045247 Recruiting - Clinical trials for Large B-cell Lymphoma

Phase 2 Trial of Epcoritamab in Combination With Rituximab-mini CVP for Older Unfit/Frail Patients or Anthracycline-Ineligible Adult Patients With Newly Diagnosed Diffuse Large B-cell Lymphoma

Start date: January 5, 2024
Phase: Phase 2
Study type: Interventional

To learn if adding epcoritamab to the treatment combination R-miniCVP (rituximab, cyclophosphamide, vincristine, prednisone) can help to control newly diagnosed DLBCL. The safety of this combination will also be studied.

NCT ID: NCT06043323 Recruiting - Follicular Lymphoma Clinical Trials

A Phase II Study of Axicabtagene Ciloleucel, an Anti-CD19 Chimeric Antigen Receptor (CAR) Tcell Therapy, in Combination With Radiotherapy (RT) in Relapsed/Refractory Follicular Lymphoma

Start date: January 8, 2024
Phase: Phase 2
Study type: Interventional

To learn about the safety of a drug called axicabtagene ciloleucel given in combination with radiation therapy to patients with relapsed/refractory FL.

NCT ID: NCT06043011 Recruiting - Clinical trials for Chronic Lymphocytic Leukemia (CLL)

Registry Platform Hematologic Malignancies (RUBIN) - Extension of Tumor Registry Lymphatic Neoplasms

RUBIN
Start date: September 27, 2023
Phase:
Study type: Observational [Patient Registry]

The purpose of the project is to set up a national, prospective, longitudinal, multicenter registry platform to document uniform data on characteristics, molecular diagnostics, treatment and course of disease, to collect patient-reported outcomes and to establish a decentralized biobank for patients with hematological malignancies in Germany.

NCT ID: NCT06037239 Recruiting - Clinical trials for Cutaneous T-cell Lymphoma

Phase I/II Study of Linperlisib Plus Chidamide for R/R Cutaneous T-cell Lymphoma: a Prospective, Single-center Study

Start date: July 1, 2023
Phase: Phase 1/Phase 2
Study type: Interventional

HDAC inhibitor chidamide and PI3K inhibitor linperlisib has shown clinical activity as mono therapy in PTCL. The combination of duvelisib and romidepsin is highly active against relapsed and refractory T-cell lymphomas including cutaneous T-cell lymphomas (CTCLs). The aim of this study is to further explore the efficacy and safety of HDAC inhibitor chidamide combined with PI3K inhibitor linperlisib in the treatment of relapsed and refractory CTCLs.

NCT ID: NCT06035497 Recruiting - Clinical trials for Relapsed or Refractory T-cell Lymphomas

A Study to Assess the Safety, Tolerability, Efficacy, and Drug Levels of BMS-986369 in Participants With Relapsed or Refractory T-cell Lymphomas in Japan

Start date: November 20, 2023
Phase: Phase 1/Phase 2
Study type: Interventional

The purpose of this study is to test the safety, tolerability, efficacy, and drug levels of BMS-986369 in participants with relapsed or refractory T-cell lymphomas in Japan.

NCT ID: NCT06033820 Recruiting - Clinical trials for Diffuse Large B-cell Lymphoma Recurrent

Zanubrutinib+Lenalidomide+R-ICE in Relapsed/Refractory DLBCL

Start date: October 12, 2023
Phase: Phase 2
Study type: Interventional

This is a prospective, single center, single arm, open label study of zanubrutinib, lenalidomide in combination with Rituximab-ICE for treatment of relapsed/refractory diffuse large B-cell lymphoma.

NCT ID: NCT06031194 Recruiting - Clinical trials for Diffuse Large B-Cell Lymphoma

Pharmacogenomics Effects on High-Dose Methotrexate Clearance in Patients With Diffuse Large B-Cell Lymphoma

Start date: May 10, 2023
Phase:
Study type: Observational

This study evaluates pharmacogenomic effects on high-dose methotrexate clearance in patients with diffuse large B-cell lymphoma.

NCT ID: NCT06029309 Recruiting - Clinical trials for Mantle Cell Lymphoma

Zanubrutinib and Tafasitamab in Mantle Cell Lymphoma

ZANU-TAFA
Start date: May 3, 2024
Phase: Phase 1/Phase 2
Study type: Interventional

The main purpose of this study to find the ideal dose for the combination treatment of Zanubrutinib and Tafasitamab in patients with mantle cell lymphoma. Another purpose is to assess how well the combination treatment works in patients with the study disease.

NCT ID: NCT06028373 Recruiting - Clinical trials for Advanced Solid Tumors

A Study of ATG-031 in Advanced Solid Tumors or B-cell Non-Hodgkin Lymphomas

Start date: December 8, 2023
Phase: Phase 1
Study type: Interventional

ATG-031 study (alias: PERFORM) is a multicenter, open-label, Phase 1 study of ATG-031 in patients with advanced solid tumors or B-NHL. The study design includes a Dose Escalation Phase and a Dose Expansion Phase, and will enroll patients with advanced solid tumors (i.e., preferred tumor types) or relapsed/refractory (R/R) B-NHLs. The study's primary objective is to evaluate the safety and tolerability of ATG-031 and determine the RP2D(Refered Phase II dose) of ATG-031.

NCT ID: NCT06027957 Recruiting - Clinical trials for B-Cell Acute Lymphoblastic Leukemia

CD19 CAR T-Cell Therapy for R/R Non-Hodgkin Lymphoma and Acute Lymphoblastic Leukemia

Start date: August 2, 2023
Phase: Phase 1
Study type: Interventional

- Brief Summary: Cluster of differentiation 19 (CD19) is expressed on B cells. CD19+ tumor cells in patients with non-Hodgkin lymphoma and acute lymphoblastic leukemia can be targeted using T cells expressing CD19-specific chimeric antigen receptor (CAR). - Objective: This study aims to evaluate the safety and efficacy of single-dose anti-CD19 CAR T-cell therapy in the treatment of relapsed/refractory CD19+ non-Hodgkin lymphoma and acute lymphoblastic leukemia. - Eligibility: People aged 1 to 60 years with relapsed/refractory CD19+ non-Hodgkin lymphoma and acute lymphoblastic leukemia. - Design: Phase 1 clinical trial, uncontrolled, single dose of CD19 CAR T-cells.